Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cyclic Peptide [R4W4] in Improving the Ability of First-Line Antibiotics to Inhibit Mycobacterium tuberculosis Inside in vitro Human Granulomas

Frontiers in Immunology(2020)10.3389/fimmu.2020.01677Source: DataRank Database

Cyclic Peptide [R4W4] in Improving the Ability of First-Line Antibiotics to Inhibit Mycobacterium tuberculosis Inside in vitro Human Granulomas is a research paper published in Frontiers in Immunology (2020). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.15)OA: goldTopics (85)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

David J. B. Ashley ORCID,Ruoqiong Cao ORCID,Rachel Abrahem,Timothy Nguyen ORCID,Kimberly To

Live enrichment

PubMed:32973740 PMC:PMC7438584 OpenAlex:https://openalex.org/W3048366075

NHLBI NIH HHS

Grant: R15 HL143545

National Institutes of Health

Grant: 2R15HL143545-02

Glutathione depletion in the CNS and its effects on Mtb infection

National Heart, Lung, and Blood Institute

FWCI

0.15

Citation Percentile

0.6%

Citation Trend

2021

2022

2023

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.01677/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.01677/pdf

publisherhttps://www.frontiersin.org/article/10.3389/fimmu.2020.01677/full

journalhttps://doi.org/10.3389/fimmu.2020.01677

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32973740

Fields of Study

Tuberculosis Research and EpidemiologyCancer therapeutics and mechanismsAntimicrobial Peptides and Activities0301 basic medicine03 medical and health sciencesAdolescentAdultAgedAntibiotics, AntitubercularAutophagyCytokinesDrug Therapy, CombinationGranulomaHost-Pathogen InteractionsHumansIsoniazidMicrobial ViabilityMiddle AgedMycobacterium tuberculosisOxidative StressPeptides, CyclicPyrazinamideTuberculosisYoung Adult

MeSH Terms

AdolescentAdultAgedAntibiotics, AntitubercularAutophagyDrug Therapy, CombinationGranulomaHumansIsoniazidMiddle AgedMycobacterium tuberculosisPeptides, CyclicPyrazinamideTuberculosisCytokinesOxidative StressMicrobial ViabilityHost-Pathogen InteractionsYoung Adult

Keywords

AntibioticsMycobacterium tuberculosisPyrazinamideTuberculosisMicrobiologyMedicineIsoniazidMinimum inhibitory concentrationPharmacologyBiologyPathologyCytokineCyclic peptideAntimicrobial peptidesHost–bacteria InteractionOther AnalyticalAdultAdolescentBacterial Infections and MycosesImmunologyTherapeuticsPeptides, CyclicYoung AdultAutophagyHumansAmino AcidsAntibiotics, Antitubercularhostâ€“bacteria interactionAgedDiagnostic and Therapeutic Techniques and EquipmentGranulomaMicrobial Viabilityand ProteinsRC581-607Middle AgedOxidative StressHost-Pathogen InteractionsCytokinesOther Pharmacy and Pharmaceutical SciencesDrug Therapy, CombinationImmunologic diseases. AllergyPeptides

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being